Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 7:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Oxymetazoline Nasal Spray Clear all
Recruiting Phase 4 Interventional

Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea

NCT02630121
View directory record Official record
Conditions
Sleep Apnea, Chronic Nasal Congestion
Interventions
Oxymetazoline Hydrochloride, Placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Sep 30, 2026, 7:14 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Pediatric Patients

NCT01844830
View directory record Official record
Conditions
Anesthesia
Interventions
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%, Placebo
Drug
Lead sponsor
St. Renatus, LLC
Industry
Eligibility
3 Years to 17 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Loma Linda, California • Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Sep 30, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TransMEM Gas Exchange -- Project 1, Aim 2

NCT01925729
View directory record Official record
Conditions
Middle Ear Disease, Nasal Allergy
Interventions
ragweed, histamine, pseudoephedrine, Oxymetazoline
Biological · Drug
Lead sponsor
Cuneyt M. Alper
Other
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Sep 30, 2026, 7:14 AM EDT
Terminated Not applicable Interventional

Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion

NCT00584662
View directory record Official record
Conditions
Chronic Rhinitis
Interventions
Oxymetazoline Hydrochloride
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2012 · Synced Sep 30, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Four-way Crossover Study of 3 Formulations of M207 With Intranasal Zolmitriptan in Healthy Volunteers

NCT03978403
View directory record Official record
Conditions
Migraine
Interventions
M207 3.8 mg "Sled" (two 1.9 mg patches made on a "Sled" coater, foil pouches), M207 3.8 mg "MACAP" (two 1.9 mg patches made on a "MACAP" coater, foil cups), M207 3.8 mg "MiniMac" (two 1.9 mg patches made on a "MiniMac" coater, foil cups, Zolmitriptan 2.5 mg/0.1 mL nasal spray [ZOMIG] single dose
Drug
Lead sponsor
Zosano Pharma Corporation
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Sep 30, 2026, 7:14 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Nasal Compression Device Study for Epistaxis

NCT05789264
View directory record Official record
Conditions
Epistaxis Nosebleed
Interventions
Nasal Compression Device, Routine Care
Device · Diagnostic Test
Lead sponsor
NasaClip
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Sep 30, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dose-Escalation Safety and Pharmacokinetic Study of K305

NCT01304316
View directory record Official record
Conditions
Anesthesia
Interventions
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
Drug
Lead sponsor
St. Renatus, LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Sep 30, 2026, 7:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Intranasal Steroids and Oxymetazoline in Allergic Rhinitis

NCT00584987
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Fluticasone furoate, Placebo Fluticasone furoate, Oxymetazoline, Placebo Oxymetazoline
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 30, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of M207 With Intranasal Zolmitriptan in Healthy Volunteers

NCT03708744
View directory record Official record
Conditions
Migraine
Interventions
A: M207 3.8mg, 30 min, upper arm, B: M207 3.8 mg, 30 min, thigh, C: M207 3.8 mg, 1 hr, upper arm, D:zolmitriptan nasal spray
Drug
Lead sponsor
Zosano Pharma Corporation
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Sep 30, 2026, 7:14 AM EDT
Completed Phase 1 Interventional

Treatment of Orthostatic Hypotension in Autonomic Failure

NCT00223691
View directory record Official record
Conditions
Autonomic Failure, Orthostatic Hypotension
Interventions
Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham)
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Sep 30, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of Kovacaine Nasal Spray in Pediatric Subjects

NCT01952990
View directory record Official record
Conditions
Anesthesia
Interventions
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
Drug
Lead sponsor
St. Renatus, LLC
Industry
Eligibility
3 Years to 17 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Sep 30, 2026, 7:14 AM EDT
Recruiting Phase 2 Interventional

Nasal Obstruction With Oxymetazoline and Corticosteroids

NCT06830109
View directory record Official record
Conditions
Nasal Obstruction
Interventions
Oxymetazoline Nasal Spray, Budesonide nasal spray
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 30, 2026, 7:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Polymerase Chain Reaction (PCR) Analysis of Nasal Polyps for Fungal DNA

NCT00739921
View directory record Official record
Conditions
Sinusitis, Nasal Polyps
Interventions
Nasal swab under endoscopic guidance
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Sep 30, 2026, 7:14 AM EDT
Recruiting Not applicable Interventional

Olfactory Biopsies

NCT07021040
View directory record Official record
Conditions
Alzheimer Disease, Smell Loss, Smell Dysfunction
Interventions
olfactory testing, Odor stimulation, Olfactory biopsy
Diagnostic Test · Other · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Sep 30, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of Kovacaine Nasal Spray (24 Hour Blood Collection)

NCT01807624
View directory record Official record
Conditions
Anesthesia
Interventions
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
Drug
Lead sponsor
St. Renatus, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Sep 30, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Effectiveness of Kovacaine Nasal Spray for Dental Anesthesia

NCT01302483
View directory record Official record
Conditions
Dental Anesthesia Efficacy
Interventions
3% tetracaine HCL with 0.05% oxymetazoline HCL, Lidocaine Injection
Drug
Lead sponsor
St. Renatus, LLC
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2015 · Synced Sep 30, 2026, 7:14 AM EDT
Terminated Phase 2 Interventional Results available

Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - Pediatric

NCT03962634
View directory record Official record
Conditions
Caries,Dental, Apical Periodontitis
Interventions
Kovanaze Nasal Spray, Articaine Injection
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
6 Years to 18 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Sep 30, 2026, 7:14 AM EDT